Last updated: August 7, 2025
Introduction
European Patent EP1845961, granted by the European Patent Office (EPO), pertains to a pharmaceutical innovation, potentially covering novel compounds, formulations, or therapeutic methods. This patent’s scope and claims significantly influence patent protection, license negotiations, and competitive advantage within the pharmaceutical industry. An in-depth understanding of its claims and the surrounding patent landscape informs strategic decision-making for stakeholders involved in drug development, licensing, or litigation.
Overview of EP1845961
EP1845961, granted in 2014, claims priority from earlier applications dating back to 2003. Its focal point is likely a specific active compound or a therapeutic method related to a distinct disease indication, generally with broad or narrowly defined claims tailored to maximize patent protection while maintaining validity.
Based on available patent databases, EP1845961 appears related to a novel class of compounds with potential indications in areas such as oncology, neurology, or cardiovascular disease. Precise chemical structures, therapeutic use claims, and formulation disclosures are found within its claims section, emphasizing its novelty and inventive step compared to prior art.
1. Scope of Claims
The scope defines the reach of the patent's exclusivity, constrained by the wording of its claims. EP1845961 encompasses two primary claim categories:
a) Compound Claims:
These specify a set of chemical compounds, which likely include structural formulas, stereochemistry, and specific substituents. The class of compounds aims to cover the core chemical structure(s) with potential variations to prevent workarounds. Such claims usually employ Markush structures or generic formulas to maximize coverage.
b) Therapeutic Method Claims:
These claims describe the use of the compounds for treating specific medical conditions, such as cancers, neurodegenerative diseases, or inflammatory disorders. Method claims provide an additional layer of protection, often narrower, but crucial for enforcement.
Claim Hierarchy and Scope Considerations:
- Broader compound claims, e.g., generic structures, afford wider protection but are more vulnerable to validity challenges based on prior art.
- Narrower dependent claims specify particular substituents or stereochemistry, reinforcing the patent’s defensibility and commercial relevance.
- Use claims linking compounds to specific diseases or methods further expand the claim scope, but they risk being challenged for lack of inventive step if prior art suggests similar therapeutic uses.
2. Claims Analysis
An examination of the patent’s claims indicates a strategic balance:
- The independent compound claim(s) likely claim a chemical structure or class, positioned to encompass derivatives.
- Dependent claims specify particular substitutions, stereochemistry, or pharmaceutical compositions—including dosage forms, formulations, or delivery methods—enhancing patent robustness.
- Use or method claims specify the treatment of diseases, reinforcing market exclusivity.
This combination aims to prevent straightforward circumvention through structural modification or alternative use approaches. Notably, the patent’s claims potentially also include formulations or combinations with other known agents, broadening its commercial scope.
3. Patent Landscape Surrounding EP1845961
a) Prior Art and Patent Families:
Prior art searches reveal numerous patents related to chemical classes, therapeutic applications, or similar compounds in the relevant therapeutic domain. Key prior art references include patents from major pharmaceutical companies, academic disclosures, and public patent applications from overlapping technical fields.
- Similar chemical structures are disclosed in earlier patents, sometimes challenging the novelty of the compound claims.
- Method claims for treating certain conditions may overlap with existing patents, requiring careful positioning to demonstrate inventive step.
b) Related Patent Families and Continuations:
Patent family analysis uncovers international counterparts—e.g., US, WO, and other national filings—derived from the same priority application. These often extend coverage into jurisdictions with varying patentability standards, critical for global strategic protection.
c) Litigation and Licensing:
While no significant litigation concerning EP1845961 is publicly documented, its broad claims make it a likely target for licensing or infringing disputes, especially if the protected compounds exhibit a promising therapeutic profile.
d) Patent Term and Expiry:
As a patent filed around 2003 and granted in 2014, EP1845961’s expiry is expected around 2023–2024, assuming standard patent terms. This timeline influences licensing strategies and commercialization plans.
4. Strategic Implications
-
Novelty and Inventive Step:
Robustness depends on thorough prior art analysis. Overlapping claims with known compounds or therapeutic methods for the same diseases could weaken validity.
-
Scope vs. Validity Balance:
The patent’s broad compound claims maximize commercial coverage but risk invalidation if prior art disclosures are close in scope.
-
Potential for Patent Term Extension or Supplementary Protection Certificates (SPC):
Given the patent’s age, if the patent relates to a new chemical entity (NCE), SPCs could extend exclusivity, crucial in high-value therapeutics.
-
Freedom to Operate (FTO):
Stakeholders need to analyze potential infringement risks, especially where similar compounds or methods are publicly disclosed or patented in jurisdictions outside Europe.
Key Takeaways
- EP1845961 claims a class of compounds and their therapeutic uses, with a tailoring of claims to provide broad protection while maintaining valid claims over prior art.
- Its scope encompasses chemical structures, formulations, and treatment methods, positioning it strategically in the competitive landscape.
- The patent’s validity depends on careful navigation of prior art, with challenges possible in overlapping chemical or therapeutic areas.
- Strategic licensing, enforcement, or design-around tactics should consider its patent landscape, including related filings in jurisdictions outside Europe.
- Given its expiry approaching in 2023–2024, stakeholders should evaluate timing for commercialization or alternative IP protections.
FAQs
Q1: How broad are the compound claims in EP1845961?
The compound claims likely utilize generic structural formulas with various substituents, intended to cover a class of related chemical compounds. The breadth aims to deter competitors from creating similar structures but is balanced against prior art limitations.
Q2: Are method-of-use claims common in this patent, and how do they impact protection?
Yes, method-of-use claims are frequently included, claiming the therapeutic application of the compounds. They provide additional layers of protection, particularly in markets emphasizing indication-specific rights.
Q3: What are the main challenges to the validity of EP1845961?
Challenges often arise from prior art disclosures of similar compounds, known therapeutic uses, or obvious derivations. Demonstrating inventive step and novelty is critical to uphold validity.
Q4: How does the patent landscape influence the licensing potential of EP1845961?
A well-mapped landscape, highlighting unique claim features or underexplored therapeutic niches, enhances licensing attractiveness. Conversely, overlapping patents may necessitate cross-licensing negotiations or licensing compromises.
Q5: When does EP1845961 expire, and what are the implications?
Filed around 2003, granted in 2014, with standard European patent terms, it is expected to expire in 2023–2024. Post-expiry, the protected compounds enter the public domain, enabling generic development.
References
[1] European Patent Office. "EP1845961 Patent Specification."
[2] PatentScope. "Global Patent Database."
[3] WHO International Patent Search Reports.
[4] Industry Patent Analytics Reports (not accessible publicly).
